{
  "docId": "019de077-5087-71ae-b0e8-0abfd1317859",
  "docSlug": "b6fff97596ca7cba1b2ee8405a1dc7cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 38 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 38,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a split-layout: left side details the clinical trial results, right side lists pipeline expansion opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5087-71ae-b0e8-0abfd1317859/20",
  "deckHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859",
  "deckJsonHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859.json",
  "deckAnchorHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.66,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Tezspire multi-billion $ opportunity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e020de9b-e2cd-43ed-8c72-df0045274b4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "list",
      "text": "Significant patient burden in patients with nasal polyps: impact on quality of life, need for surgery and systemic steroids",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74f4fc7a-9de5-45c7-accb-540da6a558e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Statistically significant, clinically meaningful reduction in: Size of nasal polyps, Nasal congestion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4c92520-df61-4479-bb6c-078ab51352d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.67,
        "y": 0.4
      },
      "kind": "list",
      "text": "Multiple Tezspire indication expansion opportunities: severe asthma (China), eosinophilic esophagitis, COPD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d762138b-08aa-43d4-85be-f625cfd6fb00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.06,
        "y": 0.78
      },
      "kind": "metric",
      "text": "7 million patients treated for nasal polyps; 3 million with uncontrolled nasal polyps (G8)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "584edc5b-0c2a-4e85-991a-49e6275ee664",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.27
      },
      "kind": "subtitle",
      "text": "Phase III WAYPOINT trial: Tezspire met both co-primary endpoints in chronic rhinosinusitis and nasal polyps",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ff38c74-7792-4441-b4bd-20d0343872ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Positive Phase III WAYPOINT trial reinforces Tezspire first-in-class mechanism of action",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f39b193-07f0-46e8-ad65-6dbcf3d29fce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d273dd16-48ee-45cb-a010-57b96d7e68ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "801eb17b-6c5b-4193-b615-ad2a5662f696",
      "evidence": "The presentation highlights the company's focus on customer needs, particularly in Oncology and BioPharmaceuticals.",
      "position": 1,
      "objective": "What are the needs and concerns of AstraZeneca's customers?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}